* Aethlon Medical Inc AEMD.OQ AEMD.O is expected to show a
rise in quarterly revenue when it reports results on August 9.
* The San Diego, California-based company is expected to report
revenue of $200 thousand, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Aethlon Medical Inc is
for a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 1.7%
in the last three months.
* Wall Street's median 12-month price target for Aethlon Medical
Inc is $9, about 41.1% above its last closing price
of $5.30.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.19 -0.20 -0.15 Beat 23.7
Dec. 31 2020 -0.17 -0.16 -0.20 Missed -21.2
Sep. 30 2020 -0.12 -0.12 -0.15 Missed -25
Mar. -0.16 -0.16 -0.22 Missed -36.2
31 2020
Dec. 31 2019 -1.03 -1.03 -0.30 Beat 70.9
Sep. 30 2019 -1.10 -1.10 -1.29 Missed -17.3
Jun. 30 2019 -1.20 -1.20 -1.35 Missed -12.5
This summary was machine generated August 6 at 21:05 GMT. All
figures in US dollars unless otherwise stated